ritlecitinib
Sponsor Pfizer INC · listed as PFE
ritlecitinib is a drug asset sponsored by Pfizer INC, listed as PFE. CSA tracks 4 forward catalysts for it — the nearest is a readout expected Dec 2, 2026 (day precision, medium confidence), tied to trial NCT07029711. That trial is in Phase 3 and currently active not recruiting, studying Severe Alopecia Areata. It appears across 6 tracked trials in the CSA sample.
Next catalyst
Trial & sponsor
All tracked catalysts for ritlecitinib
| Date | Event | Confidence | Trial |
|---|---|---|---|
| 2026-12-02 | READOUT | medium | NCT07029711 |
| 2027-03-31 | READOUT | medium | NCT06163326 |
| 2027-07-30 | READOUT | medium | NCT06072183 |
| 2028-03-19 | READOUT | medium | NCT06873945 |
Trials for ritlecitinib in the CSA sample
| Trial | Phase | Status | Primary completion | Role | Lead sponsor | Condition(s) |
|---|---|---|---|---|---|---|
| NCT07029711 catalyst | Phase 3 | Active, not recruiting | 2026-12-02 | Experimental | Pfizer | Severe Alopecia Areata |
| NCT06163326 catalyst | Phase 3 | Active, not recruiting | 2027-03-31 | Experimental | Pfizer | Vitiligo |
| NCT06072183 catalyst | Phase 3 | Active, not recruiting | 2027-07-30 | Experimental | Pfizer | Stable Nonsegmental Vitiligo; Active Nonsegmental Vitiligo |
| NCT06873945 catalyst | Phase 3 | Recruiting | 2028-03-19 | Experimental | Pfizer | Alopecia Areata |
| NCT07733765 | Phase 3 | Recruiting | 2028-04-26 | Experimental | Pfizer | Alopecia Areata |
| NCT07029828 | Phase 3 | Recruiting | 2030-06-26 | Experimental | Pfizer | Severe Alopecia Areata |
Each trial links to its ClinicalTrials.gov record; primary completion dates are as registered there.
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This page is one record from the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.
Get the full dataset — $499 → More PFE catalysts